Prognostic role of post-infarction C-reactive protein in patients undergoing implantation of cardioverter-defibrillators: Design of the C-reactive protein Assessment after Myocardial Infarction to GUide Implantation of DEfibrillator (CAMI GUIDE) study

Journal of Cardiovascular Medicine

Volumn 8, Issue 4, 2007, Pages 293-299

  Bellocci, Fulvio ^a   Biasucci, Luigi M ^a   Gensini, Gian Franco ^b   Padeletti, Luigi ^b   Raviele, Antonio ^c   Santini, Massimo ^d   Giubilato, Giovanna ^a   Landolina, Maurizio ^e   Biondi Zoccai, Giuseppe ^f   Raciti, Giovanni ^g   Sassara, Massimo ^h   Castro, Antonello ⁱ   Kheir, Antoine ^j   Crea, Filippo ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c Ospedale Umberto I   (Italy)

^d SAN FILIPPO NERI HOSPITAL   (Italy)

^e FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^f SAN RAFFAELE HOSPITAL   (Italy)

^g Guidant Italy   (Italy)

^h BELCOLLE HOSPITAL   (Italy)

ⁱ SANDRO PERTINI HOSPITAL   (Italy)

^j Policlinico San Pietro   (Italy)

more..

Author keywords

C reactive protein; Myocardial infarction; Risk stratification; Sudden cardiac death

Indexed keywords

C REACTIVE PROTEIN;

ACCURACY; ACUTE CORONARY SYNDROME; ARTICLE; CARDIOVERSION; CAUSE OF DEATH; CLINICAL ASSESSMENT; CLINICAL DECISION MAKING; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DEFIBRILLATION; DISEASE MARKER; FOLLOW UP; HEART ASSIST DEVICE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HOSPITALIZATION; HUMAN; ITALY; MAJOR CLINICAL STUDY; MORTALITY; OBSERVATIONAL STUDY; POWER ANALYSIS; PROGNOSIS; PROSPECTIVE STUDY; RISK ASSESSMENT; SUDDEN DEATH; TREATMENT PLANNING; UNSTABLE ANGINA PECTORIS;

BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; COHORT STUDIES; DATA INTERPRETATION, STATISTICAL; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; FOLLOW-UP STUDIES; HUMANS; ITALY; MYOCARDIAL INFARCTION; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; RESEARCH DESIGN; RISK ASSESSMENT; RISK FACTORS; SAMPLE SIZE; TACHYCARDIA, VENTRICULAR; TREATMENT OUTCOME; VENTRICULAR FIBRILLATION;

EID: 34247169004     PISSN: 15582027     EISSN: None     Source Type: Journal    
DOI: 10.2459/01.JCM.0000263496.52656.95     Document Type: Article

References (47)

1. Josephson M, Wellens HJJ. Implantable defibrillators and sudden cardiac death. Circulation 2004; 109:2685-2691.
2. Every N, Hallstrom A, McDonald KM, Parsons L, Thom D, Weaver D, et al. Risk of sudden versus nonsudden cardiac death in patients with coronary artery disease. Am Heart J 2002; 144:390-396.
3. Bigger JT Jr, Fleiss JL, Kleiger R, Miller JP, Rolnitzky LM. The relationships among ventricular arrhythmias, left ventricular dysfunction and mortality in the 2 years after myocardial infarction. Circulation 1984; 69:250-258.
4. Bigger JT Jr. Relation between left ventricular dysfunction and ventricular arrhythmias after myocardial infarction. Am J Cardiol 1986; 57:8B-14B.
5. Bailey JJ, Berson AS, Handelsman H, Hodges M. Utility of current risk stratification tests for predicting major arrhythmic events after myocardial infarction. J Am Coll Cardiol 2001; 38:1902-1911.
6. Owens DK, Sanders GD, Heidenreich PA, McDonald KM, Hlatky MA. Effect of risk stratification on cost-effectiveness of the implantable cardioverter defibrillator. Am Heart J 2002; 144:440-448.
7. Salukhe TV, Dimopoulos K, Sutton R, Coats AJ, Piepoli M, Francis DP. Life-years gained from defibrillator implantation: markedly nonlinear increase during 3 years of follow-up and its implications. Circulation 2004; 109:1848-1853.
8. Swedberg K, Cleland J, Dargie H, Drexler H, Follath F, Komajda S, et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005; 26:1115-1140.
9. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. ACC/AHA 2005 Guideline update for the diagnosis and management of chronic heart failure in the adult - summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2005; 46:1116-1143.
10. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, et al., for the Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002; 346:883-887.
11. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005; 352:225-237.
12. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, et al., for the Comparison of Medical Therapy, Pacing and Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac-resynchronization therapy with or without implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004; 350:2140-2150.
13. Hlatky MA, Sanders GD, Owens DK. Cost-effectiveness of the implantable cardioverter defibrillator. Card Electrophysiol Rev 2003; 7:479-482.
14. Wilber DJ, Zareba W, Hall WJ, Brown MW, Lin AC, Andrews ML, et al. Time dependence of mortality risk and defibrillator benefit after myocardial infarction. Circulation 2004; 109:1082-1084.
15. Moss AJ. MADIT-II: substudies and their implications. Card Electrophysiol Rev 2003; 7:430-433.
16. Buxton AE, Moss AJ. Should everyone with an ejection fraction less than or equal to 30% receive an implantable cardioverter-defibrillator? Not everyone with an ejection fraction < or =30% should receive an implantable cardioverter-defibrillator. Circulation 2005; 111:2537-2549.
17. Estes NA III. Primary prevention of sudden cardiac death: a rational approach to the use of the implantable cardioverter defibrillator. J Interv Card Electrophysiol 2005; 13:91-93.
18. Pedretti RF, Sarzi Braga S. Non-invasive sudden death risk stratification. Ital Heart J 2005; 6:180-189.
19. Bradley DJ, Bradley EA, Baughman KL, Berger RD, Calkins H, Goodman SN, et al. Cardiac resynchronization and death from progressive heart failure: a meta-analysis of randomized controlled trials. JAMA 2003; 289:730-740.
20. Navarro Estrada JL, Gabay JM, Alvarez J, Sztejfman C, Matas CR, Farras A, et al. Relation of C-reactive protein to extent and complexity of coronary narrowing in patients with non-ST elevation acute coronary syndromes. A prospective cohort study. Coron Artery Dis 2004; 15:477-484.
21. Biasucci LM. CDC/AHA workshop on markers of inflammation and cardiovascular disease application to clinical and public health practice clinical use of inflammatory markers in patients with cardiovascular diseases. A background paper. Circulation 2004; 110:E560-E567.
22. Kinjo K, Sato H, Ohnishi Y, Hishida E, Nakatani D, Mizuno H, et al., for the Osaka Acute Coronary Insufficiency Study (OACIS) Group. Impact of high-sensitivity C-reactive protein on predicting long-term mortality of acute myocardial infarction. Am J Cardiol 2003; 91:931-935.
23. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336:973-979.
24. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation 1999; 100:230-235.
25. Anand IS, Latini R, Florea VG, Kuskowski MA, Rector T, Masson S, et al. C-reactive protein in heart failure: prognostic value and the effect of valsartan. Circulation 2005; 112:1428-1434.
26. Lamblin N, Mouquet F, Hennache B, Dagorn J, Susen S, Bauters C, et al. High-sensitivity C-reactive protein: potential adjunct for risk stratification in patients with stable congestive heart failure. Eur Heart J 2005; 26:2245-2250.
27. Alonso-Martinez JL, Llorente-Diez B, Echegaray-Agara M, Olaz-Preciado F, Urbieta-Echezarreta M, Gonzalez-Arencibia C. C-reactive protein as a predictor of improvement and readmission in heart failure. Eur J Heart Fail 2002; 4:331-336.
28. Yin WH, Chen JW, Jen HL, Chiang MC, Huang WP, Feng AN, et al. Independent prognostic value of elevated high-sensitivity C-reactive protein in chronic heart failure. Am Heart J 2004; 147:931-938.
29. Berton G, Cordiano R, Palmieri R, Pianca S, Pagliara V, Palatini P. C-reactive protein in acute myocardial infarction: association with heart failure. Am Heart J 2003; 145:1094-1101.
30. Burke AP, Tracy RP, Kolodgie F, Malcom GT, Zieske A, Kutys R, et al. Elevated C-reactive protein values and atherosclerosis in sudden coronary death - association with different pathologies. Circulation 2002; 105:2019-2023.
31. Albert CM, Ma J, Rifai N, Stampfer MJ, Ridker PM. Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death. Circulation 2002; 105:2592-2599.
32. Biasucci LM, Giubilato G, Biondi Zoccai G, Sanna T, Liuzzo G, Piro M, et al. C-reactive protein is associated with recurrent episodes of ventricular tachycardia and ventricular fibrillation in ischemic patients with implantable cardioverter defibrillator. Presented at the 2004 Annual Scientific Sessions of the American Heart of Cardiology; November 2004; New Orleans, Louisiana, USA.
33. Harb TS, Zareba W, Moss AJ, Ridker PM, Marder VJ, Rifai N, et al. Association of C-reactive protein and serum amyloid A with recurrent coronary events in stable patients after healing of acute myocardial infarction. Am J Cardiol 2002; 89:216-221.
34. Kuck KH, Cappato R, Siebels J, Ruppel R. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH). Circulation 2000; 102:748-754.
35. Villacastin J, Almendral J, Arenal A, Albertos J, Ormaetxe J, Peinado R, et al. Incidence and clinical significance of multiple consecutive, appropriate, high-energy discharges in patients with implanted cardioverter-defibrillators. Circulation 1996; 93:753-762.
36. Tebbenjohanns J, Schumacher B, Jung W, Korte T, Pfeiffer D, Manz M, et al. Predictors of outcome in patients with implantable transvenous cardioverter defibrillators. Am Heart J 1994; 127:1086-1089.
37. Kettering K, Mewis C, Dornberger V, Vonthein R, Bosch RF, Kuhlkamp V. Efficacy of metoprolol and sotalol in the prevention of recurrences of sustained ventricular tachyarrhythmias in patients with an implantable cardioverter defibrillator. Pacing Clin Electrophysiol 2002; 25:1571-1576.
38. Pacifico A, Hohnloser SH, Williams JH, Tao B, Saksena S, Henry PD, et al., for the d,l-Sotalol Implantable Cardioverter-Defibrillator Study Group. Prevention of implantable-defibrillator shocks by treatment with sotalol. N Engl J Med 1999; 340:1855-1862.
39. Grimm W, Hoffmann JJ, Muller HH, Maisch B. Implantable defibrillator event rates in patients with idiopathic dilated cardiomyopathy, nonsustained ventricular tachycardia on Holter and a left ventricular ejection fraction below 30%. J Am Coll Cardiol 2002; 39:780-787.
40. Kadish A, Dyer A, Daubert JP, Quigg R, Estes NA, Anderson KP, et al., for the Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) Investigators. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 2004; 350:2151-2158.
41. Wolpert C, Kuschyk J, Aramin N, Spehl S, Streitner F, Suselbeck T, et al. Incidence and electrophysiological characteristics of spontaneous ventricular tachyarrhythmias in high risk coronary patients and prophylactic implantation of a defibrillator. Heart 2004; 90:667-671.
42. Hohnloser SH, Kuck KH, Dorian P, Roberts RS, Hampton JR, Hatala R, et al., for the DINAMIT Investigators. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med 2004; 351:2481-2488.
43. Raviele A, Bongiorni MG, Brignole M, Cappato R, Capucci A, Gaita F, et al. Early EPS/ICD strategy in survivors of acute myocardial infarction with severe left ventricular dysfunction on optimal beta-blocker treatment. The BEta-blocker STrategy plus ICD trial. Europace 2005; 7:327-337.
44. Bhatt D, Topol EJ. Need to test the arterial inflammation hypothesis. Circulation 2002; 106:136-140.
45. Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med 1996; 335:1933-1940.
46. Kannel WB, Thomas HE Jr. Sudden coronary death: the Framingham Study. Ann NY Acad Sci 1982; 382:3-21.
47. Anderson KP. Sudden death, hypertension and hypertrophy. J Cardiovas Pharmacol 1984; 6 Suppl 3:S498-S503.